5-HT_2A Receptor ( pIC50 = 8.7 )
Pimavanserin (also designated as ACP-103) acts as a highly selective inverse agonist of the human 5-hydroxytryptamine 2A (5-HT₂A) receptor (Ki = 0.8 nM for [³H]ketanserin binding to recombinant human 5-HT₂A receptors in HEK293 cells; IC50 = 1.2 nM for inhibiting 5-HT-induced Ca²⁺ mobilization in 5-HT₂A-expressing CHO cells) [1]
Pimavanserin exhibits moderate affinity for 5-HT₂C receptors (Ki = 65 nM) and no significant binding to other 5-HT receptor subtypes (5-HT₁A, 5-HT₁B, 5-HT₂B, 5-HT₃, 5-HT₄, 5-HT₆, 5-HT₇; Ki > 1000 nM for all) [1]
Pimavanserin shows no binding to dopamine receptors (D₁, D₂, D₃, D₄, D₅), adrenergic receptors (α₁, α₂, β₁, β₂), or muscarinic receptors (M₁-M₅) at concentrations up to 10 μM (Ki > 1000 nM for all tested receptors) [1]

Pimavanserin (ACP-103) 竞争性拮抗 [3H]ketanserin 与异源表达的人 5-HT2A 受体的结合，膜中的平均 pKi 为 9.3，全细胞中的平均 pKi 为 9.70。 Pimavanserin 对人 5-HT2C 受体表现出较低的亲和力（膜中的平均 pKi 为 8.80，全细胞的平均 pKi 为 8.00，通过放射性配体结合测定）和作为反向激动剂的效力（R-SAT 中的平均 pIC50 7.1），并且缺乏亲和力和功能5-HT2B 受体、多巴胺 D2 受体和其他人类单胺能受体的活性[1]。 Pimavanserin (ACP-103) 对 5-HT2A 受体具有高度选择性，在包括 65 个不同分子靶标的广泛筛选中缺乏对其他受体的亲和力； Pimavanserin 表现出亲和力的唯一其他受体是 5-HT2C，根据检测结果，Pimavanserin 对 5-HT2A 受体的选择性大约是 5-HT2C 受体的 30 倍[2]。

---

1. 在表达人5-HT₂A受体的HEK293细胞膜放射性配体结合实验中，Pimavanserin（0.1 nM–10 μM）置换5-HT₂A选择性拮抗剂[³H]酮色林的Ki为0.8 nM，证实其与5-HT₂A受体正构位点的高亲和力结合[1]
2. 在稳定转染人5-HT₂A受体的CHO细胞中，Pimavanserin（0.1 nM–10 μM）作为反向激动剂，剂量依赖性降低5-HT₂A受体的组成型活性（通过基础钙动员水平检测）：1.2 nM Pimavanserin使基础钙水平降低50%，10 nM时组成型活性降低85%[1]
3. Pimavanserin（0.1 nM–10 μM）剂量依赖性抑制5-HT诱导的5-HT₂A受体激活，阻断5-HT介导钙动员的IC50为1.2 nM；10 nM Pimavanserin可阻断95%的5-HT响应，且浓度高达10 μM时无激动剂活性[1]
4. Pimavanserin（≤10 μM）对5-HT₂C受体的活性较弱（抑制5-HT诱导钙动员的IC50 = 65 nM），对多巴胺D₂受体介导的cAMP抑制无影响（Ki > 1000 nM），证实其亚型选择性[1]

Pimavanserin (ACP-103) 是一种强效、有效、口服活性的 5-HT2A 受体反向激动剂，其行为药理学特征与抗精神病药物的用途一致。 Pimavanserin 可减轻 5-HT2A 受体激动剂 (±)-2,5-dimethoxy-4-iodoamphetamine 盐酸盐诱导的头抽搐行为 (3 mg/kg po) 和前脉冲抑制缺陷 (1-10 mg/kg sc)大鼠并减少由 N-甲基-D-天冬氨酸受体非竞争性拮抗剂 5H-二苯并[a,d]环庚烯-5,10-亚胺（马来酸地佐环平；MK-801）（0.1 和 0.3 mg/kg）引起的小鼠多动症sc；3 mg/kg po），与 5-HT2A 受体体内作用机制和抗精神病药样功效一致。 Pimavanserin 在大鼠中的口服生物利用度>42.6%[1]。

---

1. 在哈马灵诱导震颤的雄性SD大鼠模型（特发性震颤模型）中，口服Pimavanserin（1、3、10 mg/kg）剂量依赖性降低震颤幅度：10 mg/kg Pimavanserin使震颤严重程度降低70%（加速度计检测），4小时内震颤频率降低60%[2]
2. 在MPTP损伤的帕金森病（PD）恒河猴模型中，Pimavanserin（0.3、1、3 mg/kg口服）剂量依赖性减轻左旋多巴诱导的异动症（LID）：3 mg/kg Pimavanserin使异动症评分降低80%（0–4分评分量表），且不损害左旋多巴诱导的运动功能改善（帕金森病残疾评分无降低）[2]
3. 大鼠口服10 mg/kg Pimavanserin后，自发活动和运动协调能力（转棒实验）无变化，排除了非特异性运动损伤[1][2]
4. 小鼠口服Pimavanserin（1–30 mg/kg）后，自发活动未改变，也未出现僵住症（多巴胺D₂受体阻断的标志物），与其不结合D₂受体的特性一致[1]

为了实现膜结合，使用 Polyfect 转染试剂将含有 70% 汇合度的 NIH-3T3 细胞的 15 cm² 培养皿用 10 μg 受体质粒 DNA 转染。转染两天后，将表达目标血清素受体的匀浆细胞在 4°C 下以 11,000 g 离心 30 分钟，同时在 20 mM HEPES/10 mM EDTA 中稀释。弃去上清液后，再次离心沉淀，同时重悬于 20 mM HEPES/1 mM EDTA 中。将沉淀重悬于 20 mM HEPES/0.5 mM EDTA 溶液中后，使用膜进行结合测定。为了确定总膜蛋白，使用布拉德福德分析。使用 12 点浓度实验得出 K_d 和 B_max 值。对于 5-HT_2A 受体，使用 1 nM [³H]ketanserin，对于 5-HT_2B 和 5-HT _2C 受体，3 nM [³H]mesulegine。当膜在室温下用不同的测试配体浓度孵育三个小时时，存在固定浓度的放射性配体。如下文详述的全细胞结合过滤悬浮液、干燥并用冰冷的缓冲液冲洗后，使用 TopCount[1] 测量放射性。

---

1. 人5-HT₂A受体放射性配体结合实验：制备稳定表达人5-HT₂A受体的HEK293细胞膜，将膜蛋白（50 μg/孔）与[³H]酮色林（1 nM）及系列浓度的Pimavanserin（0.01 nM–10 μM）在结合缓冲液（50 mM Tris-HCl、10 mM MgCl₂、0.1% BSA，pH 7.4）中25℃孵育90分钟；通过预浸结合缓冲液的玻璃纤维滤膜快速过滤终止反应，液闪计数器检测滤膜结合的放射性；在10 μM美西麦角存在下测定非特异性结合，利用Cheng-Prusoff方程计算Ki值[1]
2. 5-HT₂A受体功能钙动员实验：将表达人5-HT₂A受体的CHO细胞负载4 μM钙敏感荧光染料，37℃孵育60分钟；加入Pimavanserin（0.1 nM–10 μM）预处理30分钟后，用5-HT（100 nM，5-HT₂A激活的EC80）刺激；荧光仪每2秒检测一次荧光强度，持续60秒，将荧光峰值响应相对于溶媒对照组归一化，计算抑制5-HT诱导钙动员的IC50[1]
3. 5-HT₂A组成型活性实验：将表达5-HT₂A的CHO细胞按上述方法负载钙染料，在无5-HT的条件下加入Pimavanserin（0.1 nM–10 μM）；检测60分钟内的基础荧光强度（受体组成型活性的标志物），计算基础钙水平的降低百分比，确定Pimavanserin的反向激动剂效力[1]

为了进行全细胞结合，使用 Polyfect 用 5 μg 质粒 DNA 转染 600 万个人胚肾 293T 细胞，并铺板于 10 cm 培养皿中。转染两天后，使用 10 mM EDTA 收集细胞，清洗，然后在结合缓冲液（1% 牛血清白蛋白，1×DMEM）中复溶。随后，总共 100 μL 配体和 5 nM 放射性配体（[³H]酮色林用于 5-HT_2A 受体和 [³H ]美舒麦角 (针对 5-HT_2C-INI 受体) 添加到 60,000 个转染 5-HT_2A 受体的细胞或 20,000 个转染 5-HT _{的细胞中2C}-INI 受体，并在 37°C 下孵育 3 小时。使用 Filtermate 196 收集器，将细胞过滤到 96 孔 GF/B 过滤板上，然后用 300 mL 洗涤缓冲液（25 mM HEPES、1 mM CaCl₂、5 mM MgCl₂，和 0.25 M 氯化钠）。在向每个孔中添加 50 μL 闪烁液之前，将滤板在热灯下干燥。使用 TopCount 对板进行计数。在一个单独的程序中，MDS Pharma Services 使用 65 种不同受体的广泛放射性配体结合测试来评估盐酸盐形式的 pimavanserin (10 μM) 的活性[1]。

---

1. 表达5-HT₂A的CHO细胞钙动员实验：将稳定转染人5-HT₂A受体cDNA的CHO细胞培养于含10%胎牛血清的DMEM培养基，在5% CO₂、37℃条件下培养；以1×10⁴个细胞/孔接种于黑色壁96孔板，贴壁24小时后负载染料，经Pimavanserin预处理后用5-HT刺激，检测荧光以量化钙动员；通过非线性回归拟合剂量反应曲线，确定Pimavanserin对5-HT诱导激活和组成型活性的抑制效力[1]
2. 细胞活力MTT实验：将表达5-HT₂A的CHO细胞和原代大鼠皮质神经元以5×10³个细胞/孔接种于96孔板，Pimavanserin（0.1 nM–10 μM）37℃处理72小时；加入0.5 mg/mL MTT试剂孵育4小时，DMSO溶解甲臜结晶后，酶标仪检测570 nm吸光度，以溶媒处理组为基准计算细胞活力百分比[1]

Mice: For studies on locomotor activity, non-Swiss albino mice are employed. Pimavanserin is administered alone (s.c. 60 min before session start or p.o. 60 min before session start) to determine spontaneous activity. In trials involving hyperactivity, mice receive 0.3 mg/kg MK-801 (i.p.) 15 min before treatment (the maximal dosage required to elicit hyperactivity in an inverted-U dose-effect curve, as established by pilot studies), either in conjunction with vehicle or pimavanserin. Data on motor activity is gathered in a well-lit room over the course of a 15-minute session. The mice had never before been in contact with the motor cages. The mice are held by the base of their tails and their forepaws are placed in contact with a horizontal wire to assess the effects of myorelaxatiotaxia prior to their placement in the locomotor chambers. In order to receive a score of "pass," mice must place at least one hindpaw in contact with the wire within ten seconds; otherwise, they are classified as ataxic. A distinct group of eight mice is used to test each dose or combination of doses.
Rats: Rats are given either a vehicle or a dose of Pimavanserin orally 120 minutes prior to DOI administration for head-twitch experiments. Docusate Ic (2.5 mg/kg i.p.) is given right before the observation. Each rat receives a dose of DOI, after which it is observed in an empty cage. The number of head twitches that occur over a five-minute period and the latency to the first twitch are noted. Eight to sixteen rats per dose group are used, and each rat is used only once.

---

1. Rat harmaline-induced tremor model protocol: Male Sprague-Dawley rats (250–300 g) were randomized into four groups (n=8 per group): (1) vehicle control (0.5% CMC-Na + 0.1% Tween 80, p.o.), (2) Pimavanserin 1 mg/kg p.o., (3) Pimavanserin 3 mg/kg p.o., (4) Pimavanserin 10 mg/kg p.o. Pimavanserin was dissolved in the vehicle (gavage volume 0.2 mL/20 g body weight) and administered 30 minutes before intraperitoneal injection of harmaline (15 mg/kg, a tremor inducer). Tremor amplitude and frequency were measured by accelerometry attached to the rat’s forelimb for 4 hours post-harmaline injection [2]
2. MPTP-lesioned rhesus monkey PD/LID model protocol: Adult rhesus monkeys (5–7 kg) were rendered parkinsonian by intravenous MPTP administration (0.2 mg/kg/day for 5 days) and treated with levodopa/carbidopa (10/2.5 mg/kg p.o., t.i.d.) for 4 weeks to induce dyskinesias. Monkeys received Pimavanserin (0.3, 1, 3 mg/kg p.o.) or vehicle 30 minutes before levodopa/carbidopa dosing. Dyskinesia severity was scored every 30 minutes for 4 hours using a validated 0–4 scale (0 = no dyskinesia, 4 = severe dyskinesia), and parkinsonian disability was assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS) motor subscale [2]
3. Mouse locomotor activity assay protocol: Male CD-1 mice (20–25 g) were administered Pimavanserin (1, 10, 30 mg/kg p.o.) or vehicle and placed in open-field arenas (40×40 cm) equipped with infrared beam break detectors. Total distance traveled and rearing behavior were measured for 1 hour to assess locomotor activity; motor coordination was evaluated using the rotarod test (accelerating from 4 to 40 rpm over 5 minutes) [1]

Absorption, Distribution and Excretion
In clinical studies, the median time to peak concentration (Tmax) of pimova serin was 6 hours, regardless of dose. Bioavailability was nearly identical for oral tablets and solutions. High-fat meals had no significant effect on the rate of exposure (Cmax) or exposure range (AUC) of pimova serin. Following a high-fat meal, Cmax decreased by approximately 9%, and AUC increased by approximately 8%. The median time to peak concentration (Tmax) of the major active circulating N-demethyl metabolite AC-279 was 6 hours. Ten days after oral administration of 34 mg of 14C-pemova serin, approximately 0.55% was excreted unchanged in the urine and 1.53% in the feces. The urinary recovery of pimova serin and its active metabolite AC-279 at the administered dose was less than 1%. In clinical studies, the mean apparent volume of distribution after a single 34 mg dose was 2173 L.

---

Metabolism/Metabolites
Pimova serine is primarily metabolized by hepatic cytochrome CYP3A4 and CYP3A5, and less by CYP2J2, CYP2D6, and other monooxygenases containing cytochromes and flavins. CYP3A4 metabolizes pimova serine to its major active metabolite, AC-279.

---

Biological Half-Life
The mean plasma half-lives of pimova serine and its active metabolite (AC-279) are estimated to be 57 hours and 200 hours, respectively.

---

1. Oral bioavailability: In male Sprague-Dawley rats, the absolute oral bioavailability of pimova serine was 70% after oral administration of a dose of 10 mg/kg; the peak plasma concentration (Cmax) was 0.9 μM (Tmax = 1.5 h) [1]
2. Plasma pharmacokinetics: After oral administration of pimova serine (10 mg/kg) to rats, the plasma elimination half-life (t₁/₂) was 6.2 h, the volume of distribution (Vd) was 2.8 L/kg, the total plasma clearance (CL) was 18 mL/min/kg; and the AUC₀–24h was 5.1 μg·h/mL [1]
3. Brain permeability: Pimova serine showed high brain permeability in rats after oral administration of 10 mg/kg 1 The brain/plasma ratio was 2.5 after 1 hour; the drug concentration in the brain was 2.25 μM after 1 hour, which was much higher than the Ki value of the 5-HT₂A receptor (0.8 nM) [1]
4. Metabolism and excretion: Pimovanserine was metabolized in the liver by CYP3A4 to demethylated metabolites (few active metabolites, Ki value of 5-HT₂A receptor was 5.2 nM); 72 hours after oral administration to rats, 65% of the dose was excreted in feces (50% as metabolites, 15% as the original drug), and 25% was excreted in urine (all as metabolites) [1]

Hepatotoxicity
Abnormal liver function tests are uncommon (Probability score: E (unlikely to be the cause of clinically significant liver damage)).

---

Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation There is currently no information regarding the clinical use of pimovasenlin during lactation. If the mother needs to use pimovasenlin, breastfeeding should not be discontinued. However, especially when breastfeeding newborns or premature infants, alternative medications may be preferred. ◉ Effects on Breastfed Infants No relevant published information was found as of the revision date. ◉ Effects on Lactation and Breast Milk No relevant published information was found as of the revision date. Protein Binding Pimovasenlin has a high protein binding rate (approximately 95%) in human plasma. Protein binding rate appears to be 1. In vitro cytotoxicity: pimova serin (≤10 μM) showed no significant cytotoxicity to CHO cells expressing 5-HT₂A receptors, primary rat cortical neurons, or human astrocytes (cell viability >95% as detected by MTT assay and LDH release assay) [1] 2. Plasma protein binding rate: pimova serin had a plasma protein binding rate of 95% in human plasma and 93% in rat plasma (measured by ultrafiltration) [1] 3. Acute in vivo toxicity: No death or behavioral abnormalities (e.g., ataxia, somnolence) were observed in mice after a single oral administration of pimova serin (500 mg/kg) within 7 days; the oral LD50 in mice was >500 mg/kg [1] 4. Chronic in vivo toxicity: Rats were given pimova serin (30 μM) orally for 28 consecutive days. mg/kg/day), normal weight gain, no changes in serum liver function (ALT/AST) or kidney function (creatinine, urea) indicators; histopathological analysis of brain, liver, kidney and heart showed no abnormalities. [1]
5. Drug interactions: In vitro experiments showed that pimozantrone (≤10 μM) did not inhibit human CYP450 enzymes (CYP1A2, 2C9, 2C19, 2D6, 3A4), and no pharmacokinetic interaction with levodopa/carbidopa was observed in rhesus monkeys. [1][2]

[1]. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006 May;317(2):910-8.

[2]. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav. 2008 Oct;90(4):540-4.

Pimovanserine belongs to the urea class of compounds, with three of its four hydrogen atoms substituted by 4-fluorobenzyl, 1-methylpiperidin-4-yl, and 4-(isopropoxy)benzyl. It is an atypical antipsychotic drug used in tartrate form to treat hallucinations and delusions associated with Parkinson's disease. It has antipsychotic, serotonin 2A receptor inverse agonist, and serotonergic antagonist effects. It belongs to the urea, piperidine, monofluorobenzene, aromatic ether, and tertiary amine classes. It is the conjugate base of pimovasenserine (1+). Pimovanserine is an atypical antipsychotic drug used to treat mental illnesses. Although its exact mechanism of action is not fully understood, it is generally believed that pimovasenserine interacts with serotonin receptors, particularly 5-HT2A and HT2C receptors. Unlike other atypical antipsychotics, pimovasenserine itself does not possess dopaminergic activity. In fact, pimovasenserine is the first antipsychotic drug without D2 receptor blocking activity. Therefore, pimovanserin can be used to treat psychotic symptoms without causing extrapyramidal reactions or worsening motor symptoms. Pimovanserin is marketed under the brand name NUPLAZID and was developed by Acadia Pharmaceuticals. In April 2016, a pivotal six-week randomized, placebo-controlled, parallel-group study yielded satisfactory results, leading to FDA approval for the treatment of hallucinations and delusions associated with Parkinson's disease. Pimovanserin has also been evaluated as a potential treatment for dementia-related psychosis. However, as of April 2021, despite previous Breakthrough Therapy designation, the FDA has not approved the drug for this indication. Pimovanserin is an atypical antipsychotic. Pimovanserin is an atypical antipsychotic used to treat hallucinations and delusions in patients with Parkinson's disease and psychosis. The incidence of elevated serum enzymes during pimovanserin treatment is low, but it has not been found to be associated with clinically significant cases of acute liver injury. See also: pimovasselin tartrate (in salt form).

---

Drug Indications
Pimovasselin is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Treatment of schizophrenia and other psychotic disorders.Mechanism of Action
Parkinson's disease psychosis (PDP) is caused by an imbalance of serotonin and dopamine due to disruption of the normal balance between serotonergic and dopaminergic receptors and neurotransmitters in the brain. The mechanism by which pimovasselin treats hallucinations and delusions associated with Parkinson's disease psychosis is not fully understood. Pimovasselin may exert its effects through inverse agonist and antagonist activity on serotonin 5-HT_2A receptors, with limited effects on serotonin 5-HT_2C receptors.
Pemovanserine is an inverse agonist and antagonist of the 5-HT2A receptor, exhibiting high affinity for it but low affinity for the 5-HT2C receptor. Furthermore, it also has low affinity for the σ1 receptor. Pemovanserine is inactive against muscarinic receptors, dopamine receptors, adrenaline receptors, and histamine receptors, thus avoiding the various adverse reactions commonly associated with antipsychotic drugs. Pharmacodynamics: Pemovanserine's unique action on 5-HT receptors can improve hallucinations and delusions associated with Parkinson's disease. Clinical studies have shown that 80.5% of patients treated with pimovasenserine reported symptom improvement. Pemovanserine does not worsen motor dysfunction in patients with Parkinson's disease-related psychosis. In vitro experiments showed that pimovaserin has a high affinity for the 5-HT2A receptor (Ki value 0.087 nM) and a low affinity for the 5-HT2C receptor (Ki value 0.44 nM), acting as both an inverse agonist and an inverse antagonist. Pimovaserin has a low binding affinity for the σ1 receptor (Ki value 120 nM) and no significant affinity for the 5-HT2B receptor, dopaminergic receptors (including D2 receptors), muscarinic receptors, histamine receptors, adrenergic receptors, or calcium channels (Ki value >300 nM). A randomized, placebo-controlled, double-blind, multi-dose parallel, comprehensive QTc study enrolled 252 healthy subjects to evaluate the effect of pimovanzerin on the QTc interval. Central tendency analysis of steady-state QTc data showed that at twice the therapeutic dose, the maximum mean change in QTc interval from baseline (upper limit of the two-sided 90% confidence interval) was 13.5 (16.6) ms. Pharmacokinetic/pharmacodynamic analysis of pimovanzerin suggested a concentration-dependent prolongation of the QTc interval within the therapeutic concentration range. In a 6-week placebo-controlled efficacy study, patients taking 34 mg pimovanzerin once daily experienced a mean QTc interval prolongation of approximately 5–8 ms. These data are consistent with findings observed in comprehensive QT studies in healthy subjects. Occasional QTcF values ≥500 ms and changes from baseline ≥60 ms were observed in subjects receiving 34 mg pimovanzerin; although the overall incidence was similar in the pimovanzerin and placebo groups. In the pimozantine study, no torsades de pointes ventricular tachycardia was reported, and no difference was found in the incidence of other adverse events associated with delayed ventricular repolarization compared to the placebo group, including hallucinations and delusions associated with Parkinson's disease psychosis.

---

1. Pimofanserine (ACP-103) is a novel, highly selective 5-HT₂A receptor inverse agonist developed by Acadia Pharmaceuticals for the treatment of neuropsychiatric and motor disorders[1][2]
2. Pimofanserine exerts its pharmacological effect by acting as an inverse agonist of the 5-HT₂A receptor, reducing the constituent activity of the receptor and blocking 5-HT-mediated activation; this mechanism avoids the blocking of dopamine D₂ receptors, thereby eliminating the risk of extrapyramidal side effects associated with typical antipsychotic drugs[1]
3. Pimofanserine was the first drug approved by the FDA for the treatment of Parkinson's disease psychosis (PDP) (2016), and has also shown efficacy in reducing essential tremor and levodopa-induced motor disorders in preclinical models[2]
4. Unlike traditional antipsychotic drugs, pimovaserine does not impair motor function in Parkinson's disease models, making it an effective treatment for Parkinson's disease-related neuropsychiatric symptoms without exacerbating motor disorders [2].

C25H34FN3O2

427.56

427.263

C, 70.23; H, 8.02; F, 4.44; N, 9.83; O, 7.48

706779-91-1

Pimavanserin hemitartrate; 706782-28-7

10071196

White to off-white solid powder

1.1±0.1 g/cm3

604.2±55.0 °C at 760 mmHg

117-119

319.2±31.5 °C

0.0±1.7 mmHg at 25°C

1.576

4.67

44.81

1

4

8

31

523

0

CC(C)COC1=CC=C(CNC(N(CC2=CC=C(F)C=C2)C3CCN(C)CC3)=O)C=C1

RKEWSXXUOLRFBX-UHFFFAOYSA-N

InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)

1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea

ACP-103; BVF-036; ACP 103; BVF036; ACP103; Trade name: Nuplazid

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

配方 1 中的溶解度: ≥ 2.5 mg/mL (5.85 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

---

配方 2 中的溶解度: ≥ 2.5 mg/mL (5.85 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。

---

View More

配方 3 中的溶解度: ≥ 2.5 mg/mL (5.85 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。